Published in Blood Weekly, December 16th, 2004
Under the agreement, Eisai will obtain the exclusive right to develop, manufacture, and market clevudine in 10 Asian countries excluding South Korea. Eisai will develop the compound in those Asian countries, principally in China, aiming at filing of new drug applications for approval.
Clevudine is an antiviral agent for treatment of hepatitis caused by the hepatitis B virus based on DNA polymerase inhibition. In South Korea, Bukwang is currently conducting phase III clinical trials.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.